Subcutaneous immunotherapy injections work the same way as their intravenous counterparts — by changing or enhancing a person’s immune responses to cancer. Immunotherapy for cancer is a broad ...

However, in December 2024, the Food and Drug Administration (FDA) approved a new version of nivolumab (Opdivo Qvantig) for use as a subcutaneous injection. This means a person can receive the drug ...

Satio announced today that it completed a Small Business Innovation Research (SBIR) contract for its intradermal drug ...